9:00 am
Check-in
10:00 am
Welcome
10:15 am
Session I
Navigating the bridge from lab to clinic in stem cell-based therapies
Keynote
Thomas Hassing Ronøe Carlsen (Novo Nordisk, Denmark)
Optimising efficacy of tumor-specific T cells and manufacturing scalability
Keynote
Felix Lorenz (Captain T Cell, Germany)
Engineering persistence in off-the-shelf cell therapies
Keynote
Karl-Johan Malmberg (University of Oslo, Norway)
11:45 am
Break
12:00 pm
AstraZeneca industry symposium
Supported by AstraZeneca GmbH
The evolving CAR-T landscape in multiple myeloma: Advances in design, targeting, and manufacturing
Johannes Waldschmidt (Germany)
Michael Hudecek (Germany)
12:45 pm
Break
1:30 pm
Johnson&Johnson industry symposium
Supported by J&J Innovative Medicine Janssen-Cilag GmbH
2:15 pm
Break
2:30 pm
Session II
Reprogramming the tumor microenviroment toward immune activation by targeted gene-based cytokine delivery
Keynote
Luigi Naldini (Vita-Salute San Raffaele University, Italy)
Fantastic parvoviral gene therapy vectors and how to find them
Keynote
Dirk Grimm (University of Heidelberg, Germany)
Flash Talk
Minicircle DNA for virus-free engineering of gene-modified cells
Marcello Stein (PlasmidFactory GmbH, Germany)
Supported by PlasmidFactory GmbH
Inducing immunogenic lymphoid niches across cancers by tumor-to-dendritic cell reprogramming
Gaia Fontanari (Sweden)
4:00 pm
Poster session I
PP01 – Endoplasmic reticulum stress modulation reshapes the tumor immune microenvironment and enhances dendritic cell vaccine efficacy in ovarian cancer
Barbora Vavrušáková (Czech Republic)
PP03 – Advancements in automated TIL manufacturing: Clinical-scale pre-REP and REP using CliniMACS Prodigy®
Julia Atanasov (Germany)
PP05 – Morphomechanical phenotyping of human immune cells by high-throughput deformability cytometry (DC)
Jessica Freitag (Germany)
PP07 – Assessing TCR T cell therapies for solid tumors using 3D bioprints
Xu Holtkotte (Germany)
PP09 – Evolution of CD4‑specific CAR constructs towards clinical application in NK cell therapies
Leonhard Schlosser (Germany)
PP11 – Identification of vector integration sites in Cilta-Cel-treated multiple myeloma patients
Conny Blumert (Germany)
PP13 – Multimodal profiling reveals actionable vulnerabilities in CAR T-derived T-cell lymphoma
Christina Kuhn (Germany)
PP15 – BioThrust bioreactor technology for scalable production of allogeneic NK cell therapeutics
Kristina Roth (Germany)
PP17 – Exploring low-energy electron irradiation as an alternative to extracorporeal photopheresis for GvHD treatment
Maria Schricker (Germany)
PP19 – CD19- and CD20-directed NKG2D bispecific antibodies to restore the NKG2D axis and to potently activate NK cells against leukemia cells
Katja Klausz (Germany)
PP21 – Increasing filling precision: Advances in the CliniMACS Prodigy® TCTf process
Bianca Weidemann (Germany)
PP25 – Next-generation CLEC12A-CAR-NK cells combining a novel VHH binding domain and KLRC1 disruption for AML immunotherapy
Janika Sosat (Germany)
PP29 – A single-cell, droplet-based assay for CAR-T potency profiling: Effector and target cell viability and cell-cell contact kinetics on the Envisia platform
Elisa Salis (UK)
PP31 – Microbial metabolite-guided CAR T-cell engineering enhances anti-tumor immunity
Maik Luu (Germany)
PP33 – Targeting the molecular mimicry induced by sialyl transferase-expressing C. jejuni strains during Guillain-Barré syndrome by tailor-made cellular immunotherapies
Sandra Freier (Germany)
PP35 – Scalable hollow-fiber impeller bioreactor for primary T cell expansion: Evaluation of fed-batch and perfusion modes
Felipe Veliz Valenzuela (Germany)
PP37 – Towards a universal lipid nanoparticle (LNP) platform for multiplex engineering of next- generation ex vivo cell therapies
Martin Rabel (Canada)
5:00 pm
Session III
t.b.a.
Keynote
Angela Vollstedt (Novartis, Austria)
The evolving field of cellular therapy in LBCL
Keynote
Anna Sureda (Catalan Institute of Oncology, Spain)
Longitudinal clonal tracking of ciltacabtagene autoleucel in relapsed / refractory multiple myeloma
Michael Rade (Germany)
Development of novel CAR cell therapeutics in pediatric AML
Sabrina Schuster (Germany)
6:30 pm
Get-together
9:00 am
Session IV
Flash Talk
Understanding the barriers of CAR-T therapy and development towards point-of-care operational models
Dominik Griebling (Fresenius, Germany)
Supported by Fresenius SE & Co. KGaA
Allogeneic TCR-engineered NK cells as an off-the-shelf platform for intracellular antigen targeting in infection and cancer
Frederik Feigl (Germany)
9:45 am
Break
10:00 am
Session IV
Role of microbiome for response to chemotherapy and immunotherapy in gastrointestinal cancers
Keynote
Joseph Tintelnot (Universitätsklinikum Hamburg-Eppendorf, Germany)
Decoding MSI cancers: From the immune microenvironment to response and resistance to immunotherapy
Keynote
Florence Renaud (Sorbonne University, France)
Loss of LEDGF/p75 disrupts DNA damage signaling and sensitizes patient-derived colorectal cancer cells to 5-fluorouracil
Victoria Liedtke (Germany)
Functional MMR empowers efficient cDC1 reprogramming in MSS colorectal cancer
Sandra Schwarz (Germany)
11:30 am
Break
11:45 am
BMS industry symposium
Supported by Bristol Myers Squibb GmbH & Co. KGaA
12:30 pm
Break
1:15 pm
Poster session II
PP02 – Development of CAR NK cell therapy inspired by mechanistic study of immune evasion in solid tumors
Manasa Srinivasan (India)
PP04 – Leaving SB100X behind – Development of a new hyperactive Sleeping Beauty transposase for cell engineering
Natalie Forkert (Germany)
PP06 – Investigating small molecule modulators of temozolomide and thymidine toxicity in glioblastoma multiforme
Manasvini Sridharr (Germany)
PP08 – Volatilomic and biomechanical analysis as windows into immune cell function
Emilia Flores Naranjo (Germany)
PP10 – CAR FINDER: Revolutionizing CAR T cells
Robert Serfling (Germany)
PP12 – Establishment of a cell line based antibodydependent cellular phagocytosis (ADCP) assay, using frozen assay ready cells
Felix Hackstein (Germany)
PP14 – Bridging the gap: Developing bispecific antibodies as adaptor molecules for LNP-mediated in vivo CAR T cell engineering in AML
Ela Çetin (Germany)
PP16 – Humanized mouse models for the preclinical evaluation of novel immune cell therapies, check point inhibitors, and immune cell engagers – Enhanced in vivo and ex vivo analysis enables deeper characterization
Maria Stecklum (Germany)
PP18 – Targeting B cell neoplasia with NKp30-directed bispecific natural killer cell engagers
Dorothee Winterberg (Germany)
PP20 – Lipid nanoparticle-mediated mRNA delivery for ex vivo engineering of CD123-specific CAR NK cells
Nadine von Auw (Germany)
PP24 – Dual nanobody-CAR-NK cells facilitate versatile „OR-Gated“ killing to mitigate antigen escape in AML
Kamala Bharathi Ramalingam (Germany)
PP26 – Spatial biodistribution analysis of in vivo generated CAR T cells using MICS technology
Juliane Schwarzer (Germany)
PP28 – Establishment of an in vitro epithelial-endothelial co-culture barrier model to investigate CAR-T-cell-interactions with physiological barriers
Charlotte Schwister (Germany)
PP30 – LipiGo enables extrahepatic RNA delivery as a foundation for in vivo immune-cell engineering
Ceren Kimna (Germany)
PP32 – Operational barriers drive access limitations to CAR-T cell therapy in Germany: Results from the EASYGEN multicenter survey
Dominik Griebling (Germany)
PP34 – The transmembrane adaptors SIT and TRIM as tunable negative regulators of T cell activation and checkpoint balance
Nouria Jantz-Naeem (Germany)
PP36 – Metformin alleviates CD8+ T cell exhaustion induced by cancer-conditioned adipose-derived mesenchymal stromal cells in association with reduced mitochondrial hyperpolarization
Chau Ton Nu (South Korea)
2:15 pm
Session V
In vivo CAR T cells have reached the clinical stage
Keynote
Christian Buchholz (Paul Ehrlich Institut, Germany)
Karolinska ATMP Center & future manufacturing for in vivo CAR T cell therapies
Keynote
Knut Steffensen (Karolinska Institutet, Sweden)
Keynote
Stephan Mielke (Karolinska Institutet, Sweden)
Clinical and manufacturing advances in allogeneic NK and CAR-NK cell therapy: From MRD-positive AML to autoimmune disease
Jan Spanholtz (Glycostem, The Netherlands)
A next-generation ionizable lipid LNP platform for efficient in vivo CAR T cell generation across species through passive and active immune cell targeting strategies
Martin Rabel (Cytiva, Canada)
